ABSTRACT
Background Guidelines recommend universal mismatch repair tumor (MMR) testing of colorectal adenocarcinomas (CRC) to screen for Lynch syndrome (LS). However, its implementation remains disjointed and referral for genetic testing dismal, particularly among minorities. We aimed to increase referral, cancer genetic testing, and eventually LS diagnosis by developing a systems approach which, in the second phase was automated.
Methods This is a cohort study of all patients diagnosed with CRC at an academic center between 1/1/2012 and 1/31/2021. Tumor testing included MMR immunohistochemistry, followed by BRAF V600E/MLH1 promoter methylation testing when indicated. The intervention included a manual phase, which systematized Pathology screening and cancer genetics (CG) referral mechanisms, and an automated phase utilizing computer programming.
Results A total of 249/1,541 CRC (17.38%) had MMR loss of expression and 129 (8.37%) qualified for CG evaluation. Referral was 27.58% in the original cohort and 92.1% in the intervention (p<0.001). Patients seen by CG among referred were 27.58% in the original cohort and 74.3 % in the intervention (P two-sided <0.001). The distribution of race/ethnicity among patients qualifying and referred for CG evaluation was not significantly different across cohorts. LS diagnosis increased from 0.56% (original cohort) to 1.43% (intervention). Cost per new diagnosis of LS decreased from $173,675 to $87,960 from original cohort to intervention.
Conclusion Implementation of systematic case identification and referral support mechanisms significantly increased the proportion of patients undergoing genetic testing and doubled the percentage of patients diagnosed with Lynch syndrome with no referral differences across racial/ethnic groups.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by internal funds from the Yale Cancer Center (XL); and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDKO): T32DK007356 (CM). The study sponsors had no role in the design of the study; in the collection, analysis, or interpretation of the data; in the writing of the manuscript; or in the decision to submit the manuscript for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
On May 20, 2019, The Yale University IRB determined that the proposed activity does not constitute "research" as defined in 45 CFR 46. IRB protocol number:2000025564
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding: This work was supported by internal funds from the Yale Cancer Center (XL); and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDKO): T32DK007356 (CM). The study sponsors had no role in the design of the study; in the collection, analysis, or interpretation of the data; in the writing of the manuscript; or in the decision to submit the manuscript for publication.
Data Availability: De-identified data is available upon request
Notes:
Role of the funder: Yale Cancer Center and NIDDK: salary support
Potential Competing Interests: The authors have no conflicts of interest to disclose.
Abbreviations
- AA
- African Americans
- CG
- cancer genetics
- CGPP
- Cancer Genetics and Prevention Program
- CLEAR LS
- closed loop enhanced assessment and referral for lynch syndrome study
- CRC
- colorectal adenocarcinoma
- HER
- Electronic health record
- H
- Hispanics
- IHC
- immunohistochemistry
- MSI
- microsatellite instability
- MMR
- mismatch repair
- NHW
- non-Hispanic Whites
- LS
- Lynch syndrome
- RTSE
- Repetitive Tasks Scheduling Engine
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos